First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Alpha Biopharma (Jiangsu) Co., Ltd.492 enrolled

Overview

The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC) with Central Nervous System (CNS) metastasis

This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients with advanced EGFR mutation positive NSCLC with CNS metastases. Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-naïve advanced NSCLC and documented intracranial disease will be enrolled.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

492

Conditions

Non-small Cell Lung Cancer EGFR Gene Mutation Brain Metastases

Interventions

AZD3759DRUG

AZD3759 200mg PO BID.

ErlotinibDRUG

SoC EGFRTKI Erlotinib 150 mg PO Q.D

GefitinibDRUG

SoC EGFRTKI Gefitinib 250 mg PO Q.D

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Properly completed patient informed consent 2. Male or female aged at least 18 years 3. Histologically or cytologically confirmed diagnosis of NSCLC with activating EGFR mutations including L858R and/or Exon19Del. EGFR mutation status will be determined by local or central laboratory testing on tumour tissue or plasma utilizing a validated methodology which has been approved by the regulatory authority. 4. No prior treatment with chemotherapy, EGFR-TKIs, or biological therapies that are considered first line treatment for advanced NSCLC. 5. All patients must have a documented diagnosis of advanced (Stage IV) NSCLC with Magnetic Resonance Imaging (MRI) documented CNS metastases that include brain metastases (BM). BM + patients with co- existent leptomeningeal involvement are eligible for the study. 6. Eligible patients are not candidates for definitive surgical resection or radiation of all lesions in the opinion of the treating physician. 7. All patients must be stable without any systemic (oral or parenteral) corticosteroid or anticonvulsant therapy for at least 2 weeks prior to study treatment. Inhaled non-absorbable and topical corticosteroid use are permitted as indicated. 8. Patients may have prior placement of a properly functioning CNS shunt or Ommaya reservoir. 9. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 with no deterioration over the previous 2 weeks. 10. Women of child-bearing potential and male subjects shall agree to take medically acceptable contraception measures while on study treatment and for 3 months following completion of study treatment. All women of child-bearing potential must have a negative blood pregnancy test at screening. 11. (a) For Patients with measurable CNS lesions must have AT LEAST ONE site of CNS lesion, which was not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter by MRI and which is suitable for accurate repeated measurements. Measurable extracranial disease is not required. (b) For Patients with non-measurable CNS lesions must have AT LEAST ONE extracranial lesion, which has not been previously irradiated, within the screening period that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) by CT/MRI and are suitable for accurate repeated measurement.

Locations (58)

Outcomes

Primary Outcomes

PFS assessed by Blinded Independent Central Radiological

To assess if first line treatment with AZD3759 results in significant PFS efficacy compared to Gefitinib or Erlotinib as determined by Blinded Independent Central Radiological (BICR) review using RECIST 1.1.

Time frame: 48 months

Secondary Outcomes

PFS assess by investigator

Investigator assessment of PFS using RECIST 1.1

Time frame: 48 months

Intracranial PFS (iPFS) assessed by investigator

Intracranial PFS (iPFS) assessed by investigator using RECIST 1.1

Time frame: 48 months

Intracranial PFS (iPFS) assessed by BICR

Intracranial PFS (iPFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1

Time frame: 48 months

Extracranial PFS (ePFS) assessed by investigator

Extracranial PFS (ePFS) assessed by investigator using RECIST 1.1

Time frame: 48 months

Extracranial PFS (ePFS) assessed by BICR

Extracranial PFS (ePFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1

Time frame: 48 months

Objective Response Rate (ORR） assessed by investigator using RECIST 1.1

Objective Response Rate (ORR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1

Time frame: 48 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

China site

Hefei, Anhui, China

China site

Chongqing, China, China

China site

Fuzhou, Fujian, China

China site

Xiamen, Fujian, China

China site

Guangzhou, Guangdong, China

China site

Guangzhou, Guangdong, China

China site

Haerbin, Heilongjiang, China

China site

Zhengzhou, Henan, China

China site

Zhengzhou, Henan, China

China site

Wuhan, Hubei, China

...and 48 more locations

Disease Control Rate (DCR) assessed by investigator using RECIST 1.1

Disease Control Rate (DCR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1

Time frame: 48 months

Duration of Response (DoR) assessed by investigator using RECIST 1.1

Duration of Response (DoR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1

Time frame: 48 months

Overall ORR assessed by investigator using RECIST 1.1

Time frame: 48 months

Overall DCR assessed by investigator using RECIST 1.1

Time frame: 48 months

Overall DoR assessed by investigator using RECIST 1.1

Time frame: 48 months

ORR for Intracranial lesions assessed by investigator using RANO-BM

Time frame: 48 months

DCR for Intracranial lesions assessed by investigator using RANO-BM

Time frame: 48 months

DoR for Intracranial lesions assessed by investigator using RANO-BM

Time frame: 48 months

Overall Survival

Time frame: 48 months

Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30).

The 30-items questionnaire measures cancer patients' functioning and symptoms. The scale range of EORTC QLQ-C30 is 30-126. Lower values represent a better outcome.

Time frame: 48 months

Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire BN20 (EORTC QLQ-BN20).

The 20-items questionnaire was used among brain cancer patients. The scale range of EORTC BN20 is 20-80. Lower values represent a better outcome.

Time frame: 48 months

Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)

Time frame: 48 months

Neurological function improvement rate assessed by RANO-BM criteria

Time frame: 48 months

Number of participants with treatment-related Adverse Events as assessed by CTCAE v5.0

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Time frame: 48 months

Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0

Time frame: 48 months

Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0

Time frame: 48 months

Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0

Time frame: 48 months

Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0

Time frame: 48 months

Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.

Time frame: 48 months

Systolic and Diastolic Blood Pressure assessed during the study period.

Time frame: 48 months

Pulse rate assessed during the study period.

Pulse rate to assessed during the study period.

Time frame: 48 months

Body temperature assessed during the study period.

Time frame: 48 months

PFS assess by BICR

Blinded Independent Central Radiological (BICR) assessment of PFS using modified RECIST 1.1.

Time frame: 48 months